Myoview 1.38 mg/1 (Tetrofosmin INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) 1.38 mg/1

Myoview 1.38 mg/1 is a lyophilized powder for solution, containing tetrofosmin, used for diagnostic imaging. This intravenous injection aids in evaluating cardiac function and blood flow.

Strength

1.38 mg/1

Pack Size

5 VIAL in 1 KIT (17156-026-30) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL

Manufacturer / TM Owner

Medi-Physics Inc. dba GE Healthcare

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Myoview 1.38 mg/1 is primarily used in nuclear medicine for myocardial perfusion imaging. This diagnostic tool helps assess blood flow to the heart muscle, aiding in the evaluation of coronary artery disease. Healthcare professionals may use it to identify areas of reduced blood flow, which can indicate potential heart issues.

Side Effects

When administered intravenously, Myoview 1.38 mg/1 distributes throughout the body and accumulates in the heart muscle. This accumulation allows for clear imaging, helping to highlight areas with adequate or reduced blood flow. The effects are typically observed during imaging procedures.

Precautions & Warnings

Myoview 1.38 mg/1 should be handled with care, following standard protocols for radioactive materials. It is essential to use appropriate protective measures to minimize exposure. Always consult healthcare professionals for proper administration and handling guidelines.

Avoid Interactions

Myoview 1.38 mg/1 may interact with other medications or substances, particularly those affecting heart function or blood flow. It is crucial to inform healthcare providers about all current medications to avoid potential interactions. Always follow professional advice regarding concurrent use with other treatments.

Frequently Asked Questions

Myoview 1.38 mg/1 is used for myocardial perfusion imaging to assess heart function and blood flow.

Myoview 1.38 mg/1 is administered intravenously as a lyophilized powder for solution.

Myoview 1.38 mg/1 accumulates in the heart muscle, aiding in clear imaging of blood flow.

Yes, Myoview 1.38 mg/1 should be handled with care, following standard protocols for radioactive materials.

Myoview 1.38 mg/1 may interact with medications affecting heart function or blood flow. Consult a healthcare provider for advice.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.